TVRD Stock Analysis: Buy, Sell, or Hold?
TVRD - Tvardi Therapeutics, Inc. Common Stock
$2.95
-0.22 (-6.94%)
▼
5d:
-10.61%
30d:
-16.67%
90d:
-26.62%
WAIT
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When TVRD Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: TVRD is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: TVRD is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: TVRD is currently trading at $2.95, which is considered oversold relative to its 30-day fair value range of $3.20 to $3.94.
Technical Outlook: Technically, TVRD is in a downtrend. The price is currently testing key support at $2.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.17 (+176.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TVRD is in a downtrend. The price is currently testing key support at $2.92. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $8.17 (+176.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.20 -
$3.94
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.9%)
- BULLISH: Trading 176.8% below Wall St target ($8.17)
- WARNING: Recommendation downgraded due to -10.6% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$3.20 -
$3.94
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.92
Resistance Level
$4.04
Current Trend
Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.29
Wall Street Target
$8.17
(+176.8%)
Share & Embed Analysis
Last updated: June 03, 2026 10:22 PM ET
Data refreshes hourly during market hours. Next update: 11:22 PM
Data refreshes hourly during market hours. Next update: 11:22 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TVRD showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 59 HOLD |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$101 | 60 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 56 HOLD |
|
BHVN
Biohaven Ltd. |
STRONG BUY
16 analysts |
$22 | 55 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 55 HOLD |